Open AccessHypertension and incident cardiovascular events following ibrutinib initiation
Author(s) -
Tyler Dickerson,
Tracy Wiczer,
Allyson Waller,
J Philippon,
Kyle Porter,
Devin Haddad,
Avirup Guha,
Kerry A. Rogers,
Seema A. Bhat,
John C. Byrd,
Jennifer A. Woyach,
Farrukh T. Awan,
Daniel Addison
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019000840
Subject(s) - ibrutinib , medicine , intensive care medicine , leukemia , chronic lymphocytic leukemia
In a retrospective analysis, Dickerson et al report that the incidence of hypertension in patients treated with ibruitinib is nearly 80% and is associated with an increased rate of adverse cardiovascular events, primarily atrial fibrillation. Cardiac events can be reduced by treating the hypertension.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom